Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms

Parish P. Sedghizadeh, Shuting Sun, Adam F. Junka, Eric Richard, Keivan Sadrerafi, Susan Mahabady, Neema Bakhshalian, Natalia Tjokro, Marzenna Bartoszewicz, Monika Oleksy, Patrycja Szymczyk, Mark W. Lundy, Jeffrey Neighbors, R. Graham G. Russell, Charles E. McKenna, Frank H. Ebetino

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Osteomyelitis is a major problem worldwide and is devastating due to the potential for limb-threatening sequelae and mortality. Osteomyelitis pathogens are bone-attached biofilms, making antibiotic delivery challenging. Here we describe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utilizing a “target and release” chemical strategy, which demonstrated a significantly enhanced therapeutic index versus ciprofloxacin for the treatment of osteomyelitis in vivo. In vitro antimicrobial susceptibility testing of the conjugate against common osteomyelitis pathogens revealed an effective bactericidal profile and sustained release of the parent antibiotic over time. Efficacy and safety were demonstrated in an animal model of periprosthetic osteomyelitis, where a single dose of 10 mg/kg (15.6 μmol/kg) conjugate reduced the bacterial load by 99% and demonstrated nearly an order of magnitude greater activity than the parent antibiotic ciprofloxacin (30 mg/kg, 90.6 μmol/kg) given in multiple doses. Conjugates incorporating a bisphosphonate and an antibiotic for bone-targeted delivery to treat osteomyelitis biofilm pathogens constitute a promising approach to providing high bone-antimicrobial potency while minimizing systemic exposure.

Original languageEnglish (US)
Pages (from-to)2326-2343
Number of pages18
JournalJournal of Medicinal Chemistry
Volume60
Issue number6
DOIs
StatePublished - Mar 23 2017

Fingerprint

Diphosphonates
Osteomyelitis
Ciprofloxacin
Biofilms
Bone and Bones
Anti-Bacterial Agents
Bacterial Load
Extremities
Animal Models
Safety
Mortality

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

Sedghizadeh, Parish P. ; Sun, Shuting ; Junka, Adam F. ; Richard, Eric ; Sadrerafi, Keivan ; Mahabady, Susan ; Bakhshalian, Neema ; Tjokro, Natalia ; Bartoszewicz, Marzenna ; Oleksy, Monika ; Szymczyk, Patrycja ; Lundy, Mark W. ; Neighbors, Jeffrey ; Russell, R. Graham G. ; McKenna, Charles E. ; Ebetino, Frank H. / Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 6. pp. 2326-2343.
@article{13462a98a5af45f28c219d36783f96cb,
title = "Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms",
abstract = "Osteomyelitis is a major problem worldwide and is devastating due to the potential for limb-threatening sequelae and mortality. Osteomyelitis pathogens are bone-attached biofilms, making antibiotic delivery challenging. Here we describe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utilizing a “target and release” chemical strategy, which demonstrated a significantly enhanced therapeutic index versus ciprofloxacin for the treatment of osteomyelitis in vivo. In vitro antimicrobial susceptibility testing of the conjugate against common osteomyelitis pathogens revealed an effective bactericidal profile and sustained release of the parent antibiotic over time. Efficacy and safety were demonstrated in an animal model of periprosthetic osteomyelitis, where a single dose of 10 mg/kg (15.6 μmol/kg) conjugate reduced the bacterial load by 99{\%} and demonstrated nearly an order of magnitude greater activity than the parent antibiotic ciprofloxacin (30 mg/kg, 90.6 μmol/kg) given in multiple doses. Conjugates incorporating a bisphosphonate and an antibiotic for bone-targeted delivery to treat osteomyelitis biofilm pathogens constitute a promising approach to providing high bone-antimicrobial potency while minimizing systemic exposure.",
author = "Sedghizadeh, {Parish P.} and Shuting Sun and Junka, {Adam F.} and Eric Richard and Keivan Sadrerafi and Susan Mahabady and Neema Bakhshalian and Natalia Tjokro and Marzenna Bartoszewicz and Monika Oleksy and Patrycja Szymczyk and Lundy, {Mark W.} and Jeffrey Neighbors and Russell, {R. Graham G.} and McKenna, {Charles E.} and Ebetino, {Frank H.}",
year = "2017",
month = "3",
day = "23",
doi = "10.1021/acs.jmedchem.6b01615",
language = "English (US)",
volume = "60",
pages = "2326--2343",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "6",

}

Sedghizadeh, PP, Sun, S, Junka, AF, Richard, E, Sadrerafi, K, Mahabady, S, Bakhshalian, N, Tjokro, N, Bartoszewicz, M, Oleksy, M, Szymczyk, P, Lundy, MW, Neighbors, J, Russell, RGG, McKenna, CE & Ebetino, FH 2017, 'Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms', Journal of Medicinal Chemistry, vol. 60, no. 6, pp. 2326-2343. https://doi.org/10.1021/acs.jmedchem.6b01615

Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms. / Sedghizadeh, Parish P.; Sun, Shuting; Junka, Adam F.; Richard, Eric; Sadrerafi, Keivan; Mahabady, Susan; Bakhshalian, Neema; Tjokro, Natalia; Bartoszewicz, Marzenna; Oleksy, Monika; Szymczyk, Patrycja; Lundy, Mark W.; Neighbors, Jeffrey; Russell, R. Graham G.; McKenna, Charles E.; Ebetino, Frank H.

In: Journal of Medicinal Chemistry, Vol. 60, No. 6, 23.03.2017, p. 2326-2343.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms

AU - Sedghizadeh, Parish P.

AU - Sun, Shuting

AU - Junka, Adam F.

AU - Richard, Eric

AU - Sadrerafi, Keivan

AU - Mahabady, Susan

AU - Bakhshalian, Neema

AU - Tjokro, Natalia

AU - Bartoszewicz, Marzenna

AU - Oleksy, Monika

AU - Szymczyk, Patrycja

AU - Lundy, Mark W.

AU - Neighbors, Jeffrey

AU - Russell, R. Graham G.

AU - McKenna, Charles E.

AU - Ebetino, Frank H.

PY - 2017/3/23

Y1 - 2017/3/23

N2 - Osteomyelitis is a major problem worldwide and is devastating due to the potential for limb-threatening sequelae and mortality. Osteomyelitis pathogens are bone-attached biofilms, making antibiotic delivery challenging. Here we describe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utilizing a “target and release” chemical strategy, which demonstrated a significantly enhanced therapeutic index versus ciprofloxacin for the treatment of osteomyelitis in vivo. In vitro antimicrobial susceptibility testing of the conjugate against common osteomyelitis pathogens revealed an effective bactericidal profile and sustained release of the parent antibiotic over time. Efficacy and safety were demonstrated in an animal model of periprosthetic osteomyelitis, where a single dose of 10 mg/kg (15.6 μmol/kg) conjugate reduced the bacterial load by 99% and demonstrated nearly an order of magnitude greater activity than the parent antibiotic ciprofloxacin (30 mg/kg, 90.6 μmol/kg) given in multiple doses. Conjugates incorporating a bisphosphonate and an antibiotic for bone-targeted delivery to treat osteomyelitis biofilm pathogens constitute a promising approach to providing high bone-antimicrobial potency while minimizing systemic exposure.

AB - Osteomyelitis is a major problem worldwide and is devastating due to the potential for limb-threatening sequelae and mortality. Osteomyelitis pathogens are bone-attached biofilms, making antibiotic delivery challenging. Here we describe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utilizing a “target and release” chemical strategy, which demonstrated a significantly enhanced therapeutic index versus ciprofloxacin for the treatment of osteomyelitis in vivo. In vitro antimicrobial susceptibility testing of the conjugate against common osteomyelitis pathogens revealed an effective bactericidal profile and sustained release of the parent antibiotic over time. Efficacy and safety were demonstrated in an animal model of periprosthetic osteomyelitis, where a single dose of 10 mg/kg (15.6 μmol/kg) conjugate reduced the bacterial load by 99% and demonstrated nearly an order of magnitude greater activity than the parent antibiotic ciprofloxacin (30 mg/kg, 90.6 μmol/kg) given in multiple doses. Conjugates incorporating a bisphosphonate and an antibiotic for bone-targeted delivery to treat osteomyelitis biofilm pathogens constitute a promising approach to providing high bone-antimicrobial potency while minimizing systemic exposure.

UR - http://www.scopus.com/inward/record.url?scp=85016333912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016333912&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b01615

DO - 10.1021/acs.jmedchem.6b01615

M3 - Article

VL - 60

SP - 2326

EP - 2343

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 6

ER -